TD Cowen Initiates Coverage On Recursion Pharmaceuticals with Market Perform Rating
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Steven Mah has initiated coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Market Perform rating.
January 26, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Recursion Pharmaceuticals receives a Market Perform rating from TD Cowen, indicating a neutral outlook on the stock.
The initiation of coverage by an analyst typically brings a stock into focus for investors. A Market Perform rating suggests that the analyst believes the stock will perform in line with the market, neither outperforming nor underperforming significantly. This neutral stance is likely to have a muted impact on the stock price in the short term, as it does not suggest a strong buy or sell sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100